Trial Profile

A Blinded, Randomized, Placebo-controlled, Multiple Dose Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ESK-001 Tablets Administered Over 14days to Healthy Participants

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ESK-001 (Primary)
Indications Autoimmune disorders; Psoriasis; Systemic lupus erythematosus; Uveitis
Focus Adverse reactions
Sponsors Alumis

12 Mar 2024 Results from ESK001-002 and ESK001-003, presented at the American Academy of Dermatology annual Meeting 2024
04 Mar 2024 According to Alumis media release, the company will highlight pharmacokinetic and pharmacodynamic data of healthy participants from this study during e-poster presentation at the American Academy of Dermatology Annual Meeting taking place March 8-12, 2024, in San Diego, CA.
06 May 2023 Status changed from recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com